UK markets closed

Sartorius Stedim Biotech S.A. (0RG8.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
367.44+27.78 (+8.18%)
At close: 05:45PM GMT

Sartorius Stedim Biotech S.A.

Zone Industrielle Les Paluds
Avenue de Jouques – CS 91051 Cedex
Aubagne 13781
France
33 4 42 84 56 00
https://www.sartorius.com

Sector(s)
Industry
Full-time employees10,662

Key executives

NameTitlePayExercisedYear born
Dr. Rene FaberCEO & DIrector540kN/A1975
Mr. Rainer LehmannCFO & Member of Executive BoardN/AN/A1975
Ms. Petra MullerHead of Investor RelationsN/AN/AN/A
Ms. Petra KirchhoffHead of Corporate Communications & IRN/AN/A1969
Olivier GuitardHead of Controlling BPSN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Corporate governance

Sartorius Stedim Biotech S.A.’s ISS governance QualityScore as of 1 February 2024 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.